The ultimate goal of precision medicine is a unique drug for each patient. However, this N-of-1 model directly conflicts with the current economic and regulatory system, which incentivizes developing drugs for large populations to recoup massive R&D and approval costs.

Noetik's core thesis is that the 95% failure rate in cancer trials isn't due to bad drug design, but an inability to identify the correct patient sub-population. Their models aim to solve this patient selection problem from the outset, rescuing potentially effective drugs.

The extreme effectiveness of frontline BEP chemotherapy makes it nearly impossible to replace. This forces novel drug development into the small, refractory patient population. This niche market makes it economically challenging for pharmaceutical companies to invest in large-scale trials, thus slowing innovation for new agents.

As AI enables early disease prediction (like Grail's cancer test), the number of sick patients will decrease. This erodes the traditional drug sales model, forcing pharma companies to create new revenue streams by monetizing predictive data and insights.

The standard approach to reducing cancer drug toxicity is narrowing the target to specific mutations (e.g., HER2, KRAS). While this improves safety, it drastically shrinks the addressable patient population for each new therapy. This puts immense pressure on the pharmaceutical business model, where development costs average $2.5 billion per drug.

With over 5,000 oncology drugs in development and a 9-out-of-10 failure rate, the current model of running large, sequential clinical trials is not viable. New diagnostic platforms are essential to select drugs and patient populations more intelligently and much earlier in the process.

The fastest, cheapest path to drug approval involves showing a small survival benefit in terminally ill patients. This economic reality disincentivizes the longer, more complex trials required for early-stage treatments that could offer a cure.

Effective new antibiotics are used sparingly to prevent resistance, which makes them commercially unviable for pharma companies. This "vicious circle" of low usage leading to low revenue actively disincentivizes the development of the very drugs needed to combat superbugs.

Pharmaceutical companies view the healthcare market as a battle for a patient's total spending capacity. They lobby against non-patentable compounds like peptides not because they have a direct competitor, but because every dollar spent on a compounded peptide is a dollar not spent on one of their high-margin, patented prescription drugs, thus protecting their overall revenue.